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Paolo Guidetti
Paolo Guidetti passed away on December 28, 2007 at age 41, a victim of a brief, devastating bout with 
lymphoma. His death deprives the ﬁ  eld of tryptophan research of one of its brightest and most promising 
young stars. We also mourn the loss of a unique individual, who not only had an outstanding mind but 
possessed an exceptional ability to inspire and to foster collaborations and friendships.
Paolo was born into a prominent family in Reggio Emilia, one of the major cities of Italy’s 
Emilia-Romagna region. During his graduate education at the nearby University of Modena, where he 
was mentored by the eminent neuroscientist Mario Baraldi, he began to develop a deep-seated interest 
in the brain and decided to pursue postdoctoral work in a neuroscience-related ﬁ  eld in the United States. 
Recognizing Paolo’s potential, and much to my beneﬁ  t as it would turn out, Baraldi suggested that he 
join me in Baltimore to study molecular mechanisms involved in neurodegeneration. During the 1980s, 
we had performed a series of studies implicating the peripheral tryptophan metabolites (“kynurenines”) 
quinolinic acid and kynurenic acid in the pathophysiology of Huntington’s Disease (HD) and other 
neurodegenerative diseases, but we still had only a very rudimentary view of the neurobiology of these 
compounds when Paolo arrived. Soon after setting foot in the laboratory, Paolo showed that L-kynurenine, 
rather than tryptophan itself, serves as the primary source of both quinolinate and kynurenate in the brain. 
In subsequent years, he focused especially on the biology of kynurenate, identifying kynurenine ami-
notransferase II (KAT II) as its most relevant biosynthetic enzyme in the brain. Using experimental 
lesions and immunocytochemical methods, he then localized KAT II to astrocytes and suggested that 
glia-derived kynurenate might play an active role in brain physiology. This idea, which was developed 
while Paolo was still a postdoctoral fellow, has stood the test of time. Due to the realization that endog-
enous kynurenate tonically modulates glutamatergic, dopaminergic and cholinergic function, the 
original concept has, in fact, more recently blossomed into the attractive hypothesis that ﬂ  uctuations in 
brain kynurenate control cognitive processes in the mammalian brain. The obvious conjecture—that 
astrocytic KAT II might be targeted pharmacologically to inﬂ  uence cognitive function—occupied much 
of Paolo’s time during his ﬁ  nal months and would certainly have been a major focus of his career had 
his life not been tragically cut short.
To readers of this journal, Paolo may be best known for his work on HD. Based on a series of clever 
experiments in the late 1990s, he concluded that 3-hydroxykynurenine (3-HK), a bioprecursor of quinolinate, 
may enhance quinolinate-induced neurodegeneration due to the generation of reactive free radicals. In 
rapid succession, he showed that 3-HK indeed dramatically potentiated the excitotoxic effects of quinolinate 
in the rat striatum in vivo and documented that the brain levels of 3-HK were substantially elevated in 
several of the newly developed mouse models of HD. These ﬁ  ndings, together with his subsequent 
demonstration that the brain tissue content of both 3-HK and quinolinate is greatly increased in the early 
stages of the disease, rejuvenated and galvanized the decade-old idea that an excitotoxic mechanism might 
underlie HD pathology. Moreover, these studies, together with the work of others who had shown that 
3-HK and quinolinate are preferentially formed in microglial cells, added an important new twist to the 
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hypothesis, suggesting that neurodegeneration in HD is non-cell autonomous in nature. More speciﬁ  cally, 
Paolo’s results indicated that the neurotoxic effects of mutant huntingtin, the protein that initiates the 
pathological cascade, might depend on the activation of microglial kynurenines. As a corollary, it became 
evident that interventions aimed at preventing or arresting the formation of microglial kynurenines might 
render the effects of the mutant protein less severe or even innocuous. At the time of his passing, Paolo 
had designed a number of imaginative genetic and pharmacological approaches to test this attractive 
hypothesis and its implications for the treatment of HD.
Paolo’s discoveries and the development of his exciting concepts were a direct consequence of his 
ability to think creatively, his willingness to embark on technically demanding, high-risk projects, an 
impressive no-nonsense, “can-do” attitude, and—maybe most importantly—an uncanny ability to 
identify and pursue scientiﬁ  cally important questions. But there was far more to Paolo than talent and 
professional success. Regular attendees of ISTRY (International Society for Tryptophan Research) 
meetings will remember him as an energetic, lively and optimistic, and at the same time a kind and 
generous colleague, to list but a few of the adjectives used to describe Paolo in the many messages sent 
by mourners from all corners of the world.
Paolo’s approach to life and people brought the best out in everyone, yet his ﬂ  ame shone far too 
brieﬂ  y. I will personally miss a wonderful scientiﬁ  c companion, who had a brilliant future ahead of 
him. There is apparent truth to the old saying that only the good die young. It was a privilege to have 
him in our lives. He will not be forgotten.
Robert Schwarcz,
University of Maryland School of Medicine,
Baltimore, MD (U.S.A).